Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept plus MMF or low-dose steroids in IgA nephropathy with low proteinuria
ChiCTR2600130830Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Shantou University Medical College
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of telitacicept in IgA nephropathy (IgAN) (2 arms), sponsored by The Second Affiliated Hospital of Shantou University Medical College. Primary endpoints: Urine protein-to-creatinine ratio and Estimated glomerular filtration rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2600130830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130830.